top of page

White House’s Drug Patent Plan Undercuts Research and Innovation

On Dec. 7, the White House announced a plan it claims will lower prescription drug costs.

It centers on using a 43-year-old law—the Bayh-Dole Act—to let government officials force patent owners to cancel existing licenses, and instead license their patents to generic companies so they can make and sell cheaper copies. That amounts to seizing private patent rights.


コメント


bottom of page